Dr Rebecca McQualter — CEO, Chimeric Therapeutics Rebecca joined Chimeric Therapeutics in May 2024, bringing senior experience from roles at Novartis, Amgen and GlaxoSmithKline. She holds a Doctor of Philosophy in Cell Therapy and Regenerative Medicine from Monash University. Dr McQualter has an extensive commercial career with exposure to many aspects of international pharmaceutical operations. Prior to joining Chimeric, she was Head of Strategic Access at Novartis Australia, where she developed new commercial partnerships with the likes of Telstra and Wesfarmers as well as building external networks spanning policy makers, research institutes and NGOs, while engaging with federal and state government, trade associations and other stakeholders.